This Plain Language Summary of publication article (PLSP) from Future Oncology pooled data from three clinical trials involving over 400 patients with 33 different cancer types treated with futibatinib, a drug targeting FGFR proteins linked to cancer growth. Researchers analyzed the frequency, timing, and management of side effects and offered recommendations for healthcare professionals.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients’ and was published in the Clinical Cancer Research.

Visit AACR using the link to read the original article.